- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04014881
Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.
Single-center, Open-label, Single-arm Clinical Study of Efficacy and Safety of Anti-CD123 CAR-T Therapy in Patients With Refractory/Relapsed CD123+ Acute Myeloid Leukemia.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Recruiting
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Pathological and histological examination confirmed CD123+ refractory or relapsed Acute Myeloid Leukemia.
A. Diagnostic criteria for recurrent AML: After complete remission (CR), leukemia cells or bone marrow primordial cells > 0.050 (except for bone marrow regeneration after consolidation chemotherapy) or extramedullary leukemia cell infiltration appears again in peripheral blood.
B.Diagnostic criteria for refractory AML(Meeting one of the following)
i. ineffectiveness after the first standard regimen treatment of 2 courses.
ii. patients relapse within 12 months after consolidation and intensive treatment after CR.
iii. Patients relapse 12 months later and fail to respond to conventional chemotherapy.
iv. Patients with two or more recurrences.
v. Patients with persistent extramedullary leukemia.
vi. Patients with recurrence after CR and unsuitable for HSCT (auto/allo-HSCT).
- Aged 18 to 70 years (including 18 and 70 years old).
- At least one measurable or evaluable lesion:AML patients with positive or relapsed positive bone marrow MRD.
- ECOG≤ 2 and expected lifetime ≥3 months.
Adequate organ function:
A. Liver function: ALT/AST≤3 ULN. Total bilirubin≤2 ULN.
B. Renal function: eGFR> 60 mL/min/1.73 m2, or creatinine clearance ≥45mL/min.
C. Lung function: Carbon Monoxide (DLCO) or Forced Expiratory Volume in the first second (FEV1) > 45% predicted.
D. Cardiac function: LVEF ≥ 50%.
- The patients did not receive any anticancer treatments such as chemotherapy, radiotherapy and immunotherapy (such as immunosuppressive drugs) within 4 weeks before admission, and the toxicity related to previous treatments had returned to < 1 level at admission (except for low toxicity such as alopecia).
- Women of child-bearing potential and all male participants must use effective methods of contraception for at least 12 months after infusion.
- Informed Consent/Assent: All subjects must have the ability to understand and the willingness to sign a written informed consent.
Exclusion Criteria:
- Women who are pregnant (urine/blood pregnancy test positive) or lactating.
- Male or female with a conception plan in the past 1 years.
- Patients cannot guarantee effective contraception (condom or contraceptives, etc.) within 1 years after enrollment.
- Uncontrolled infectious disease within 4 weeks prior to enrollment.
- Active hepatitis B/C virus.
- HIV infected patients.
- Suffering from a serious autoimmune disease or immunodeficiency disease.
- The patient is allergic and is allergic to macromolecular biopharmaceuticals such as antibodies or cytokines.
- The patient participated in other clinical trials within 6 weeks prior to enrollment.
- Systemic use of hormones within 4 weeks prior to enrollment (except for patients with inhaled corticosteroids).
- Suffering from mental illness.
- Patient has drug abuse/addiction.
- Central nervous system involvement.
- According to the investigator's judgment, the patient has other unsuitable grouping conditions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CD123+ Acute Myeloid Leukemia
Patients will receive CD123-targeted CAR-T cells in the dose-climbing trial.
Each dose group has 3 patients and the the maximum dose can be extended.
|
From the minimum dose, If no DLT emerges in the group, then the next group uses the subsequent higher dose.
If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-related Adverse Events
Time Frame: 3 years
|
Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0).
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall remission rate(ORR) of anti-CD123 CAR-T Therapy in patients with refractory/relapsed CD123+ Acute Myeloid Leukemia
Time Frame: 3 years
|
ORR will be assessed from the first CAR-T cell infusion to death or last follow-up (censored).
|
3 years
|
Overall survival(OS) of anti-CD123 CAR-T cells in patients with refractory/relapsed CD123+ Acute Myeloid Leukemia
Time Frame: 3 years
|
OS will be assessed from the first CAR-T cell infusion to death or last follow-up (censored).
|
3 years
|
Duration of Response(DOR) of anti-CD123 CAR-T cells in patients with refractory/relapsed CD123+ Acute Myeloid Leukemia
Time Frame: 3 years
|
DOR will be assessed from the first CAR-T cell infusion to death or last follow-up (censored).
|
3 years
|
Progress-free survival(PFS) of anti-CD123 CAR-T cells in patients with refractory/relapsed CD123+ Acute Myeloid Leukemia
Time Frame: 3 years
|
PFS will be assessed from the first CAR-T cell infusion to death or last follow-up (censored).
|
3 years
|
Rate of anti-CD123 CAR-T cells in bone marrow cells and peripheral blood cells
Time Frame: 3 years
|
In vivo (bone marrow and peripheral blood) rate and quantity of anti-CD123 CAR-T cells were determined by means of flow cytometry.
|
3 years
|
Quantity of anti-CD123 CAR copies in bone marrow cells and peripheral blood cells
Time Frame: 3 years
|
In vivo (bone marrow and peripheral blood) quantity of anti-CD123 CAR copies were determined by means of qPCR.
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Hansrivijit P, Gale RP, Barrett J, Ciurea SO. Cellular therapy for acute myeloid Leukemia - Current status and future prospects. Blood Rev. 2019 Sep;37:100578. doi: 10.1016/j.blre.2019.05.002. Epub 2019 May 11.
- Arcangeli S, Rotiroti MC, Bardelli M, Simonelli L, Magnani CF, Biondi A, Biagi E, Tettamanti S, Varani L. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia. Mol Ther. 2017 Aug 2;25(8):1933-1945. doi: 10.1016/j.ymthe.2017.04.017. Epub 2017 May 4.
- Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger A, von Bonin M, Bejestani EP, Ehninger G, Bachmann MP. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 2016 Aug 12;6(8):e458. doi: 10.1038/bcj.2016.61.
- Tettamanti S, Biondi A, Biagi E, Bonnet D. CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics? Oncoimmunology. 2014 May 14;3:e28835. doi: 10.4161/onci.28835. eCollection 2014.
- Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood. 2017 Apr 27;129(17):2395-2407. doi: 10.1182/blood-2016-08-736041. Epub 2017 Feb 28.
- Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang WC, Bretzlaff W, Chang B, Jonnalagadda M, Starr R, Ostberg JR, Jensen MC, Bhatia R, Forman SJ. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013 Oct 31;122(18):3138-48. doi: 10.1182/blood-2012-12-474056. Epub 2013 Sep 12.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WHUH-CART-CD123-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CD123+ Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on Third-generation anti-CD123 CAR-T cells
-
Southwest Hospital, ChinaUnknown
-
Wuhan Union Hospital, ChinaWuhan Bio-Raid Biotechnology Co., Ltd.UnknownB Cell Lymphoma | Acute Lymphoblastic LeukemiaChina
-
Hebei Senlang Biotechnology Inc., Ltd.Hebei Yanda Ludaopei HospitalUnknownAcute Myelocytic LeukemiaChina
-
Chongqing Precision Biotech Co., LtdRecruitingLeukemia | Leukemia, Myeloid | Leukemia, Myeloid, AcuteChina
-
Chongqing Precision Biotech Co., LtdRecruitingLeukemia | Leukemia, Myeloid | Leukemia, Myeloid, AcuteChina
-
Fujian Medical UniversityUnknown
-
Wuhan Sian Medical Technology Co., LtdWuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaboratorsUnknownB Cell Lymphoma | Acute Lymphoblastic LeukemiaChina
-
Shenzhen Geno-Immune Medical InstituteThe Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...Recruiting
-
Shenzhen Geno-Immune Medical InstituteRecruiting
-
Seattle Children's HospitalThe Evan Foundation; Ben Towne Center for Childhood Cancer ResearchActive, not recruitingNeuroblastoma | GanglioneuroblastomaUnited States